Bosutinib | Interleukin Related interleukin-related.com

Product Name :
Bosutinib

Search keywords :
Tyrosine Protein Kinase HCK

drugId :
null

Target Vo:
Tyrosine-protein kinase SRC

Target Vo Short Name :
SRC

Moa_Name:
Tyrosine-protein kinase SRC inhibitors

First Approval Country :
United States

First Approval Date Filter:
2012

Origin Company_Name :
Pfizer Inc

Active Company_Name :
Georgetown University

Active Indication_Name:
Leukemia, Myelogenous, Chronic

In Active Indication_Name:
Polycystic Kidney, Autosomal Dominant

Termination Status :

China Termination Status :
Phase 3 Clinical

Highest Status:
Approved

China Highest Status:
Discontinued

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Osocimab manufacturer
PARP1 Rabbit mAb In Vitro
TXNIP Antibody: TXNIP Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 44 kDa, targeting to TXNIP. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts